: The deposition of beta-sheet fibrils in Alzheimer's disease (AD) brain has been hypothesized to be the primary cause of this devastating neurodegenerative disease. These deposits include the amyloid-beta (Abeta) protein in plaques and vascular amyloid and hyper-phosphorylated tau protein in neurofibrillary tangles, dystrophic neurites and neuropil threads. Despite the presence of this characteristic neuropathology and its critical importance in the pathophysiology of the disease, no non-invasive technique has been validated to assess the presence of these deposits in living patients. The absence of such a technique hinders early and presymptomatic diagnosis and will severely hinder the development of immune therapies aimed at prevention or reversal of beta-sheet fibril deposition. Over the past decade, our laboratory has worked to develop an in vivo beta-sheet amyloid fibril imaging agent. This work has resulted in a promising lead agent, [N-methyl-11C]2(-4'-methylaminophenyl-benzothiazole (or [11C]BTA-1) which: 1) readily enters and clears from normal rodent and baboon brain; 2) binds to synthetic Abeta with nanomolar affinity; 3) specifically stains plaques and tangles in post-mortem AD brain; 4) binds to homogenates of post-mortem AD brain frontal cortex at >10-fold higher levels than aged control brain and non-AD demented brain samples, but shows no increased binding in AD cerebellum; and 5) shows no evidence of acute toxicity in preliminary studies. Furthermore, preliminary in vivo studies using APP transgenic mice and low resolution PET scanning show increased accumulation in the transgenic mice. In this study, we propose to validate the use of [11C]BTA-1 for in vivo amyloid imaging in PS/APP transgenic mice using a small animal microPET scanner. We will correlate in vivo results with: 1) quantitative immunohistochemical and histochemical measures of amyloid deposition; 2) Abeta ELISA; and 3) ex-vivo [11C]BTA-1 levels and post-mortem [3H]BTA-1 binding. We will show feasibility of longitudinal studies of the [11C]BTA-1/microPET technique in PS/APP mice and apply the technique to study an immune therapy protocol in these mice. Our goal is to provide a tool for use by investigators developing improved immune therapy protocols in transgenic mice, thus speeding progress in this area. However, because all of the techniques developed in this proposal apply directly to human studies, completion of this study will greatly speed the development of this technology for use in human studies of anti-amyloid therapies (immune therapy and secretase inhibitor therapies).

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG020226-02
Application #
6532584
Study Section
Special Emphasis Panel (ZAG1-PCR-5 (O4))
Program Officer
Buckholtz, Neil
Project Start
2001-09-30
Project End
2006-07-31
Budget Start
2002-08-01
Budget End
2003-07-31
Support Year
2
Fiscal Year
2002
Total Cost
$353,050
Indirect Cost
Name
University of Pittsburgh
Department
Psychiatry
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Mathis, Chester A; Kuller, Lewis H; Klunk, William E et al. (2013) In vivo assessment of amyloid-? deposition in nondemented very elderly subjects. Ann Neurol 73:751-61
D'Angelo, Gina M; Weissfeld, Lisa A (2013) Application of copulas to improve covariance estimation for partial least squares. Stat Med 32:685-96
Mathis, Chester A; Mason, N Scott; Lopresti, Brian J et al. (2012) Development of positron emission tomography ?-amyloid plaque imaging agents. Semin Nucl Med 42:423-32
Lin, Kuo-Shyan; Debnath, Manik L; Mathis, Chester A et al. (2009) Synthesis and beta-amyloid binding properties of rhenium 2-phenylbenzothiazoles. Bioorg Med Chem Lett 19:2258-62
Venneti, Sriram; Lopresti, Brian J; Wang, Guoji et al. (2009) PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol Aging 30:1217-26
Wolk, David A; Price, Julie C; Saxton, Judy A et al. (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65:557-68
Grimmer, Timo; Riemenschneider, Matthias; Förstl, Hans et al. (2009) Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65:927-34
Aizenstein, Howard Jay; Nebes, Robert D; Saxton, Judith A et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65:1509-17
Bolmont, Tristan; Haiss, Florent; Eicke, Daniel et al. (2008) Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci 28:4283-92
Klunk, William E (2008) Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist. Arch Neurol 65:1281-3

Showing the most recent 10 out of 30 publications